Literature DB >> 1505618

The pharmacokinetics of tiopronin and its principal metabolite (2-mercaptopropionic acid) after oral administration to healthy volunteers.

B Hercelin1, P Leroy, A Nicolas, C Gavriloff, D Chassard, J J Thébault, M T Reveillaud, M F Salles, P Netter.   

Abstract

We have studied the pharmacokinetics of tiopronin and its principal metabolite, 2-mercaptopropionic acid (2-MPA) in healthy volunteers after the oral administration of 500 mg (2 Acadione tablets), followed by simultaneous assay of the two compounds in plasma over a period of 48 h using a new method (emission of fluorescence after HPLC and post-column derivatization by pyrene-maleimide). The absorption of tiopronin was slow (tmax between 4 and 6 h) and the plasma concentrations subsequently fell biexponentially. The principal metabolite 2-MPA appeared later in the plasma (tmax between 10 and 12 h after a lag-time of 3 h) then disappeared monoexponentially. About 15% of the tiopronin was metabolized to 2-MPA.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1505618     DOI: 10.1007/bf02280762

Source DB:  PubMed          Journal:  Eur J Clin Pharmacol        ISSN: 0031-6970            Impact factor:   2.953


  15 in total

1.  [Basic treatment of rheumatoid arthritis with tiopronin. A study of 25 cases].

Authors:  M Mordini; G Guidoni; M Maestrini; A Buonavia; A Lavagni
Journal:  Minerva Med       Date:  1989-09       Impact factor: 4.806

2.  Pharmacokinetics of intravenous 2-mercaptopropionylglycine in man.

Authors:  S M Carlsson; T Denneberg; B M Emanuelsson; B Kågedal; S Lindgren
Journal:  Eur J Clin Pharmacol       Date:  1990       Impact factor: 2.953

3.  [Studies on thiol and disulfide compounds. I. Absorption distribution metabolism and excretion of 35 S-2-mercaptopropionylglycine].

Authors:  T Chiba; H Kitoo; N Toshioka
Journal:  Yakugaku Zasshi       Date:  1973-01       Impact factor: 0.302

Review 4.  Clinical pharmacokinetics of D-penicillamine.

Authors:  P Netter; B Bannwarth; P Péré; A Nicolas
Journal:  Clin Pharmacokinet       Date:  1987-11       Impact factor: 6.447

5.  [Long-term tolerability of tiopronin (Acadione) in the treatment of rheumatoid arthritis. Apropos of 140 personal cases].

Authors:  J Sany; B Combe; D Verdie-Petibon; A Tagemouati; J P Daures
Journal:  Rev Rhum Mal Osteoartic       Date:  1990-02

6.  Determination of 2-mercaptopropionylglycine in plasma and urine by high-performance liquid chromatography.

Authors:  B Kågedal; M Carlsson; T Denneberg
Journal:  J Chromatogr       Date:  1986-08-02

7.  Long-term outcome with gold thiosulphate and tiopronin in 200 rheumatoid patients.

Authors:  G F Ferraccioli; F Salaffi; A Nervetti; P Manganelli
Journal:  Clin Exp Rheumatol       Date:  1989 Nov-Dec       Impact factor: 4.473

8.  2-Mercaptopropionate, a novel metabolite formed during treatment with 2-mercaptopropionyl-glycine in cystinuria.

Authors:  J Mårtensson; T Denneberg; B Kågedal
Journal:  Eur J Clin Pharmacol       Date:  1986       Impact factor: 2.953

9.  High-performance liquid chromatographic determination of 2-mercapto-propionylglycine (thiopronine) in urine.

Authors:  V Springolo; W Bertani; G Coppi
Journal:  J Chromatogr       Date:  1982-11-12

10.  [Tolerability and therapeutic maintenance of tiopronin, new basic treatment of rheumatoid arthritis. Apropos of long-term follow-up of 268 cases].

Authors:  G Delecoeuillerie
Journal:  Rev Rhum Mal Osteoartic       Date:  1989-04-30
View more
  2 in total

1.  Changes in clearance create pharmacokinetic pitfalls as illustrated by studies on tiopronin.

Authors:  P A Sjöström
Journal:  Eur J Clin Pharmacol       Date:  1994       Impact factor: 2.953

2.  Pharmacokinetics of oral tiopronin.

Authors:  M S Carlsson; T Denneberg; B M Emanuelsson; B Kågedal; S Lindgren
Journal:  Eur J Clin Pharmacol       Date:  1993       Impact factor: 2.953

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.